While rivals scramble to merge, the world’s biggest law firm is playing the long game July 30, 2026 While rival law firms grapple with mergers and headline tie‑ups, Dentons, the world’s largest law firm by size, is quietly betting that an ‘already there’ strategy will play in its favour. Dentons’ global chief executive Kate Barton told City AM the firm, like much of Big Law, is focused on globalised client relationships: “We have [...]
Hélène Darroze à la carte is the ultimate lunchtime luxury July 30, 2026 When it comes to fine dining, who says we shouldn’t have a choice, writes Carys Sharkey There is a continual grumble in fine dining, a tedious debate that flares up every now and again when a critic complains about a sore arse from sitting through a tasting menu. I love tasting menus. I should get [...]
Scotland is a warning of what Andy Burnham’s devolution experiment will look like July 30, 2026 For an idea of what left-wing devolution yields, look no further than Scotland, where SNP statist’s efforts to extort the wealthy have backfired, writes Joseph Dinnage For a socialist, Andy Burnham has a funny approach to central government. Unlike his forebears across the former Soviet Union, southeast Asia and Latin America, the King of the [...]
I’m a 21-year-old grad, why does the government want me to go on the dole to get a job? July 30, 2026 Oliver Dean was turned away from Job Centre because he wasn’t already on benefit. No wonder the welfare bill is ballooning Andy Burnham’s answer to youth unemployment has arrived. It begins with 14-year-olds, and the new technical pathways reach classrooms in September 2028. There is a great deal to be said for it and, as [...]
People read less: Do we still need the Booker Prize? July 30, 2026 The world and it’s reading habits have changed – but has the Booker Prize changed too? And what purpose does it fulfil, asks Eliot Wilson What is the point of literary prizes? The longlist for this year’s Booker Prize was announced on Tuesday, 13 works of long-form fiction by writers of any nationality, which must [...]
Michael Dell, Lord Johnson and the ‘gun to the head’ meeting that ended a £15bn AI project July 30, 2026 In December, billionaire Michael Dell opened an alarming email. “My trust in Mr Bellamy has been undermined by the way he has operated”, the email read, “and I cannot be certain the information he shared with you is accurate or complete”. The mysterious missive was sent by Patrick Hughes, the co-founder of a major new [...]
Here’s the right way to criticise the media July 30, 2026 Did you catch Elon Musk’s blockbuster 90-minute interview with the Economist editor Zanny Minton Beddoes? It starts off with Musk’s predictions about the future of AI, which are interesting and alarming in equal measure. A lot of them sound far-fetched – will we really never need to work again in 10 years’ time? – but [...]
Everest Reports Second Quarter 2026 Results July 29, 2026 Annualized 14.2% Net Income ROE and 14.9% Net Operating Income ROE Annualized Total Shareholder Return of 16.8% $559 million of Net Income and Combined Ratio of 92.0% $317 million of Underwriting Income and Combined Ratio of 90.0% from our Core Businesses* Repurchased $395 million of Common Shares During the Quarter
Andab could be Talk of New York on Sussex Downs July 29, 2026 WE WILL take an early look at tFriday’s card where TALK OF NEW YORK is a hot favourite to win the Group Three HKJC World Pool Thoroughbred Stakes (2.25pm). This son of Wootton Bassett was an excellent third to Bow Echo and Gstaad in the Group One St James’s Palace Stakes last month. That form [...]
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026 July 29, 2026 Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva Six-month follow-up CLARITY data further reinforce a more favourable injection experience with long-acting cabotegravir compared with lenacapavir after a single dose; additional studies showcase high real-world adherence and a preference for Apretude among previous oral PrEP users EXTEND 4M explores a new investigational intramuscular cabotegravir formulation dosed three times a year for HIV prevention, as part of broader long-acting pipeline data